Abstract 1462P
Background
As nutritional management of patients with gastroesophageal cancer represents a challenge, it is surmised that nutritional parameters can be associated with cancer development and progression. The aim of this study was to investigate the impact of nutritional parameters on the outcome of these patients, so novel diagnostic, prognostic and even potentially therapeutic markers can be defined.
Methods
We analyzed clinical and laboratory parameters including dysphagia and weight-loss as well as laboratory analyses of electrolytes, Albumin and C-reactive protein at first cancer diagnosis and correlated these with the overall survival (OS) of patients with resectable gastroesophageal cancer treated between 2002 and 2018 at the Vienna General Hospital, Austria.
Results
In total, the survival outcome of 867 patients (155 stage I, 276 stage II and 423 stage III) was evaluated. Lower levels of Albumin were associated with a poorer OS (p=0.023, HR=0.971). Patients with no dysphagia had a longer survival than patients with moderate and severe (median OS 42.8 versus 22.4 versus 23.1 months, respectively; p<0.001) dysphagia. Furthermore, a tendency that patients with weight-loss might have a shorter OS than patients without weight-loss could be observed (16.4 versus 23.6 months, p=0.099).
Conclusions
Clinical and laboratory nutritional markers at first diagnosis might be associated with the OS in patients with resectable gastroesophageal cancer. Since data on the correlation of these parameters are scarce, this analysis is an important impulse for further studies concerning the impact of nutrition on patients with gastroesophageal tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.C. Puhr: Travel/Accommodation/Expenses: Eli Lilly; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Novartis. A.S. Berghoff: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Roche; Honoraria (self): Bristol-Meyers Squibb; Honoraria (self): Merck; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: AbbVie. M. Preusser: Honoraria (self): Bayer; Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Gerson Lehrman Group (GLG); Honoraria (self): GlaxoSmithKline; Honoraria (self): CMC Contrast; Honoraria (self): Mundipharma; Honoraria (self): Roche; Honoraria (self): MedMedia; Honoraria (self): Astra Zeneca; Honoraria (self): AbbVie; Honoraria (self): Lilly; Honoraria (self): Medahead; Honoraria (self): Daiichi Sankyo; Honoraria (self): MSD. A. Ilhan-Mutlu: Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (institution): Astellas; Honoraria (institution): BMS. All other authors have declared no conflicts of interest.